San Francisco-based biotech industry maven Steve Burrill said today his investment firm has raised $313 million for a new life sciences fund.
The Burrill Capital Fund IV started operations on December 1 with $313 million to make a wide variety of early and late-stage investments in companies working on drugs, diagnostics, and medical devices, as well as healthcare delivery technologies, wellness, and digital health. Burrill said in a statement that the financing represents the first close for the fund, which he hopes will reach a final goal of raising $500 million by June.
To read the full, original article click on this link: Burrill Raises $313M for New Life Sciences Fund | Xconomy
